Epirubicin (4-Epidoxorubicin), a semisynthetic L-arabino derivative of doxorubicin, acts as an antineoplastic agent by inhibiting Topoisomerase, thus impeding DNA and RNA synthesis. Additionally, it functions as a Forkhead box protein p3 (Foxp3) inhibitor, curbing regulatory T cell activity.